SCHEMBL6504059

SCHEMBL6504059

Cc1ccc(-c2cccc(-n3cc(NC(N)=O)c(C(N)=O)n3)c2)cc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.45
SCN9A Q15858 1/20 0.42
IRAK4 Q9NWZ3 6/20 0.40
LMNA P02545 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 6/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
GAA P10253 1/20 0.38
ESRRA P11474 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HTT P42858 1/20 0.37
MAPT P10636 4/20 0.37
NPSR1 Q6W5P4 1/20 0.36
KCNH2 Q12809 1/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6505904 0.87 ITK (0.48) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6501255 0.87 ITK (0.45) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6501657 0.86 ITK (0.44) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6503522 0.85 ITK (0.48) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6499548 0.84 ITK (0.45) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6504845 0.84 ITK (0.46) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6470665 0.84 ITK (0.46) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6506096 0.84 SCN9A (0.48) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6498355 0.84 KDM4E (0.47) ITKSCN9AIRAK4LMNAKDM4E
SCHEMBL6467349 0.83 ITK (0.46) ITKSCN9AIRAK4LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 ITK 4236/4885SCN9A 4159/4885IRAK4 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.